Compounds > 5-aminoorotic acid
Page last updated: 2024-11-06

5-aminoorotic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-Aminoorotic acid (5-AOA) is a pyrimidine analogue that inhibits the synthesis of uridine monophosphate (UMP) by competitively inhibiting the enzyme orotate phosphoribosyltransferase. This inhibition leads to a buildup of orotic acid in the body. 5-AOA has been studied extensively in both animal models and humans as a potential therapeutic agent for various diseases, including cancer, autoimmune disorders, and viral infections. However, its use in humans has been limited due to its toxicity. Studies indicate that 5-AOA can be synthesized through a multi-step process involving the reaction of orotic acid with ammonia. 5-AOA has demonstrated antitumor activity in vitro and in vivo against a range of cancer cell lines. Its mechanism of action is believed to involve inhibiting DNA synthesis and cell proliferation.'

5-aminoorotic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID73018
CHEMBL ID1615017
SCHEMBL ID190140
MeSH IDM0526495

Synonyms (49)

Synonym
5-amino-6-carboxy-2,4-dihydroxypyrimidine
BB 0242394
5-amino-2,6-dioxo-1,2,3,6-tetrahydro-pyrimi dine-4-carboxylic acid
4-pyrimidinecarboxylic acid, 5-amino-1,2,3,6-tetrahydro-2,6-dioxo-
7164-43-4
nsc-43249
nsc43249
orotic acid, 5-amino-
orothic acid, 5-amino-
5-aminoorotic acid
nsc 43249
einecs 230-514-2
5-amino-2,6-dioxo-1,2,3,4-tetrahydropyrimidine-4-carboxylic acid
orotic acid, 5-amino- (van)
5-aminoorotic acid, 99%
5-aminouracil-6-carboxylic acid
A0947
5-amino-2,4-dioxo-1h-pyrimidine-6-carboxylic acid
ijz ,
5-amino-2,6-dihydroxypyrimidine-4-carboxylic acid
5-amino-2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic acid
STK801850
STK803136
AKOS000119771
A837272
AKOS005622613
CHEMBL1615017
BBL012268
unii-um0f8vqr7m
um0f8vqr7m ,
FT-0620024
BBL027999
SCHEMBL190140
DTXSID1064582
BS-3932
4-pyrimidinecarboxylic acid, 5-amino-2,6-dihydroxy-
AC-10135
sr-01000529572
SR-01000529572-1
mfcd00010563
5-amino-2,4-dihydroxy-pyrimidine-6-carboxylic acid
Q27461426
F18836
5-amino-orotic acid
5-amino-2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinecarboxylic acid
5-amino-2,4-dihydroxypyrimidine-6-carboxylic acid
5-amino-1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinecarboxylic acid
EN300-19511
Z104474086
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID545994Inhibition of Trypanosoma cruzi dihydroorotate dehydrogenase by isothermal titration calorimetry2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
AID545995Inhibition of Leishmania major dihydroorotate dehydrogenase by isothermal titration calorimetry2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's3 (50.00)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.78 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
orotic acid
Orotic Acid: An intermediate product in PYRIMIDINE synthesis which plays a role in chemical conversions between DIHYDROFOLATE and TETRAHYDROFOLATE.. orotic acid : A pyrimidinemonocarboxylic acid that is uracil bearing a carboxy substituent at position C-6.		3.3660pyrimidinemonocarboxylic acidEscherichia coli metabolite;
metabolite;
mouse metabolite
uric acid
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.. uric acid : An oxopurine that is the final oxidation product of purine metabolism.. 6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.. 7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.		2.0510uric acidEscherichia coli metabolite;
human metabolite;
mouse metabolite
oxonic acid
Oxonic Acid: Antagonist of urate oxidase.		2.05101,3,5-triazines;
monocarboxylic acid
coumarin-3-carboxylic acid
coumarin-3-carboxylic acid: structure given in first source		2.1310coumarins
lanthanum
[no description available]		7.3110f-block element atom;
lanthanoid atom;
scandium group element atom
razoxane
Razoxane: An antimitotic agent with immunosuppressive properties.		7.0410N-alkylpiperazine
potassium superoxide
[no description available]		2.2510
5-fluoroorotic acid
5-fluoroorotic acid: inhibits the dietary induction of serine dehydratase. 5-fluoroorotic acid : A pyrimidinemonocarboxylic that is orotic acid which is substituted by fluorine at position 5. It is used in yeast molecular genetics to detect expression of the URA3 gene, which encodes orotine-5'-monophosphate dicarboxylase. A yeast with and active URA3 gene converts 5-fluoroorotic acid to fluorodeoxyuridine, which is toxic to cells.		2.0510
fenton's reagent
Fenton's reagent: used for oxidizing sugars & alcohols		2.1310
gallium
Gallium: A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.. gallium atom : A metallic element predicted as eka-aluminium by Mendeleev in 1870 and discovered by Paul-Emile Lecoq de Boisbaudran in 1875. Named in honour of France (Latin Gallia) and perhaps also from the Latin gallus cock, a translation of Lecoq.		2.6920boron group element atom
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		2.1310benzenes;
hydroxycoumarin;
methyl ketone
8-azaxanthine
methanochondroitin: a heteropolysaccharide from cell wall which resembles the eukaryotic chondroitin		2.0510triazolopyrimidines
allopurinol
Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.		2.6920nucleobase analogue;
organic heterobicyclic compound		antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials